Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Analyzing Combination of Olverembatinib and Pdt-All-2016 Protocol in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Next Previous
Trial Profile

A Study Analyzing Combination of Olverembatinib and Pdt-All-2016 Protocol in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olverembatinib (Primary) ; Antineoplastics
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 21 Aug 2023 According to an Ascentage Pharma media release, the clinical data of olverembatinib in pediatric patients with Ph+ ALL were published in a renowned international scientific journal for the first time. These results demonstrated favorable efficacy and safety olverembatinib in the studied patients.
  • 25 Jul 2023 New trial record
  • 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top